Specifications
- Purity
- ≥98% (HPLC)
- Appearance
- Off-white powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO (10 mg/ml), ethanol (5 mg/ml), DMF (10 mg/ml), water (insoluble)
- Melting Point
- 114-116° C
Category: Phytochemicals
Combretastatin A4 is a natural stilbenoid phenol originally isolated from an African shrub, Combretum caffrum. It is a potent inhibitor of tubulin polymerization and displays strong inhibitory activity on tumor cell growth. It inhibits tubulin polymerization at the colchicine-binding site of beta-tubulin. CA4 was shown to impede tumor growth in several cell lines including IMR32 (neuroblastoma), Hs746T (gastric carcinoma), CFPAC-1 (pancreatic carcinoma) and MCF-7 (breast cancer). It has antitumor activity by inhibiting AKT function in human gastric cells. The inhibited AKT activation causes decreased cell proliferation, cell cycle arrest and reduced in vitro migration/invasiveness and in vivo metastatic ability. Combretastatin A-4 is the active component of combretastatin A-4 phosphate, a prodrug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis. Combretastatin A-4 is therefore a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis.
Synonyms | 1-(3,4,5-Trimethoxyphenyl)-2-(3'-hydroxy-4'-methoxyphenyl) ethane 3,4,5-trimethoxy-3'-hydroxy-4'-methoxystilbene, CA4, CRC 87-09, NSC 817373 |
---|---|
Purity | ≥98% (HPLC) |
Appearance | Off-white powder |
CAS-Number | 117048-59-6 |
Molecular Formula | C18H20O5 |
Molecular Weight | 316.35 |
Identity | 1H-NMR |
Solvents | DMSO (10 mg/ml), ethanol (5 mg/ml), DMF (10 mg/ml), water (insoluble) |
Melting Point | 114-116° C |
Smiles | OC1=CC(/C=CC2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC |
InChi Key | HVXBOLULGPECHP-WAYWQWQTSA-N |
Shipping | AMBIENT |
Short Term Storage | -20°C |
Long Term Storage | -20°C |
Handling Advice | Protect from light and moisture. |
Use / Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Hazard statements | H301 + H311 + H331-H318 |
Precautionary statements | P261-P280-P301 + P310-P305 + P351 + P338-P311 |
GHS Symbol | GHS05+GHS06 |
Signal word | Danger |
Transportation | Packing Group III |
References | (1) A.T. McGown & B.W. Fox, Anticancer Drug Des. 3, 249 (1989), (2) R.T. Dorr, et al., Invest. New Drugs 14, 131 (1996), (3) J. Griggs, et al., Int. J. Oncol. 19, 821 (2001), (4) J. Griggs, et al., Lancet Oncol. 2, 82 (2011) (Review), (5) G.C. Tron, et al., J. Med. Chem. 49, 3033 (2006) (Review), (6) L.M. Greene, et al., Biochem. Pharmacol. 84, 612 (2012), (7) W. Liang, et al., Med. Sci. Monit. 22, 4911 (2016) |
InChi | InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5- |
Quantity | 10 mg, 50 mg, Bulk |